{"id":62964,"date":"2026-04-13T14:07:35","date_gmt":"2026-04-13T06:07:35","guid":{"rendered":"https:\/\/flcube.com\/?p=62964"},"modified":"2026-04-13T14:07:36","modified_gmt":"2026-04-13T06:07:36","slug":"telix-and-regeneron-forge-575m-radiopharmaceutical-alliance-to-advance-precision-oncology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62964","title":{"rendered":"Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology"},"content":{"rendered":"\n<p><strong>Telix Pharmaceuticals Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/TLX:ASX\">ASX: TLX<\/a>) and <strong>Regeneron Pharmaceuticals, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/REGN:NASDAQ\">NASDAQ: REGN<\/a>) have announced a strategic global alliance to co-develop and commercialize next-generation <strong>radiopharmaceutical therapies<\/strong> for multiple solid tumor targets. The deal leverages Telix\u2019s established radiopharma platform and Regeneron\u2019s industry-leading <strong>bispecific antibody<\/strong> discovery engine, marking a significant convergence of two cutting-edge therapeutic modalities.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-financial-terms\">Deal Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Telix Pharmaceuticals (ASX: TLX) &amp; Regeneron (NASDAQ: REGN)<\/td><\/tr><tr><td><strong>Initial Upfront Payment<\/strong><\/td><td>$40 million to Telix<\/td><\/tr><tr><td><strong>Potential Milestone Payments<\/strong><\/td><td>Up to $535 million to Telix<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Low-double-digit on net sales (if Telix opts out of co-funding)<\/td><\/tr><tr><td><strong>Profit Sharing<\/strong><\/td><td>50\/50 on global commercialization for co-funded programs<\/td><\/tr><tr><td><strong>Co-Promotion<\/strong><\/td><td>Telix retains rights for certain products<\/td><\/tr><tr><td><strong>Diagnostic Assets<\/strong><\/td><td>Jointly developed; Telix leads commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-synergies\">Strategic Synergies<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Integration:<\/strong> The collaboration merges <strong>Telix&#8217;s<\/strong> global <strong>radiopharmaceutical manufacturing<\/strong> and supply chain with <strong>Regeneron&#8217;s VelocImmune<\/strong> technology, which generates high-affinity human antibodies.<\/li>\n\n\n\n<li><strong>Target Pipeline:<\/strong> Focuses on multiple undisclosed <strong>solid tumor<\/strong> targets from Regeneron\u2019s proprietary antibody portfolio, creating a robust pipeline of potential theranostic pairs.<\/li>\n\n\n\n<li><strong>Theranostics Approach:<\/strong> The partnership explicitly includes the co-development of companion <strong>diagnostic radiopharmaceuticals<\/strong> to enable precise patient selection and real-time treatment monitoring, a cornerstone of modern precision oncology.<\/li>\n\n\n\n<li><strong>Risk\/Reward Flexibility:<\/strong> The agreement offers Telix a flexible funding model, allowing it to either co-invest for higher profit share or opt for a royalty stream with substantial milestone payments, de-risking its capital allocation.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Radiopharma Validation:<\/strong> This high-profile deal between a pure-play radiopharma leader and a top-tier biotech giant validates the growing importance of radiopharmaceuticals as a major pillar in cancer treatment.<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> The alliance positions both companies at the forefront of the next wave of targeted cancer therapies, combining the tumor-targeting precision of bispecific antibodies with the potent cell-killing ability of radioisotopes.<\/li>\n\n\n\n<li><strong>Financial Catalyst:<\/strong> The immediate $40 million upfront provides Telix with non-dilutive capital, while the potential $575 million total value per program represents a massive upside for shareholders.<\/li>\n\n\n\n<li><strong>Global Reach:<\/strong> The global nature of the profit-sharing and commercialization rights ensures that any successful therapy will have a worldwide launch strategy from inception.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief outlines the terms of a newly announced strategic collaboration. The development of radiopharmaceuticals is subject to significant scientific, regulatory, and commercial risks. There can be no assurance that any product candidates will receive regulatory approval or achieve commercial success. Milestone payments are contingent upon achieving specific development and sales targets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Telix Pharmaceuticals Ltd. (ASX: TLX) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced a strategic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2403,1166,1426,2402],"class_list":["post-62964","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-asx-tlx","tag-nasdaq-regn","tag-regeneron-pharmaceuticals","tag-telix-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Telix Pharmaceuticals Ltd. (ASX: TLX) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced a strategic global alliance to co-develop and commercialize next-generation radiopharmaceutical therapies for multiple solid tumor targets. The deal leverages Telix\u2019s established radiopharma platform and Regeneron\u2019s industry-leading bispecific antibody discovery engine, marking a significant convergence of two cutting-edge therapeutic modalities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62964\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology\" \/>\n<meta property=\"og:description\" content=\"Telix Pharmaceuticals Ltd. (ASX: TLX) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced a strategic global alliance to co-develop and commercialize next-generation radiopharmaceutical therapies for multiple solid tumor targets. The deal leverages Telix\u2019s established radiopharma platform and Regeneron\u2019s industry-leading bispecific antibody discovery engine, marking a significant convergence of two cutting-edge therapeutic modalities.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62964\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T06:07:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T06:07:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62964#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62964\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology\",\"datePublished\":\"2026-04-13T06:07:35+00:00\",\"dateModified\":\"2026-04-13T06:07:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62964\"},\"wordCount\":408,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ASX: TLX\",\"NASDAQ: REGN\",\"Regeneron Pharmaceuticals\",\"Telix Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62964#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62964\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62964\",\"name\":\"Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-13T06:07:35+00:00\",\"dateModified\":\"2026-04-13T06:07:36+00:00\",\"description\":\"Telix Pharmaceuticals Ltd. (ASX: TLX) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced a strategic global alliance to co-develop and commercialize next-generation radiopharmaceutical therapies for multiple solid tumor targets. The deal leverages Telix\u2019s established radiopharma platform and Regeneron\u2019s industry-leading bispecific antibody discovery engine, marking a significant convergence of two cutting-edge therapeutic modalities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62964#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62964\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62964#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology - Insight, China&#039;s Pharmaceutical Industry","description":"Telix Pharmaceuticals Ltd. (ASX: TLX) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced a strategic global alliance to co-develop and commercialize next-generation radiopharmaceutical therapies for multiple solid tumor targets. The deal leverages Telix\u2019s established radiopharma platform and Regeneron\u2019s industry-leading bispecific antibody discovery engine, marking a significant convergence of two cutting-edge therapeutic modalities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62964","og_locale":"en_US","og_type":"article","og_title":"Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology","og_description":"Telix Pharmaceuticals Ltd. (ASX: TLX) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced a strategic global alliance to co-develop and commercialize next-generation radiopharmaceutical therapies for multiple solid tumor targets. The deal leverages Telix\u2019s established radiopharma platform and Regeneron\u2019s industry-leading bispecific antibody discovery engine, marking a significant convergence of two cutting-edge therapeutic modalities.","og_url":"https:\/\/flcube.com\/?p=62964","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-13T06:07:35+00:00","article_modified_time":"2026-04-13T06:07:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62964#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62964"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology","datePublished":"2026-04-13T06:07:35+00:00","dateModified":"2026-04-13T06:07:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62964"},"wordCount":408,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ASX: TLX","NASDAQ: REGN","Regeneron Pharmaceuticals","Telix Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62964#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62964","url":"https:\/\/flcube.com\/?p=62964","name":"Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-13T06:07:35+00:00","dateModified":"2026-04-13T06:07:36+00:00","description":"Telix Pharmaceuticals Ltd. (ASX: TLX) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced a strategic global alliance to co-develop and commercialize next-generation radiopharmaceutical therapies for multiple solid tumor targets. The deal leverages Telix\u2019s established radiopharma platform and Regeneron\u2019s industry-leading bispecific antibody discovery engine, marking a significant convergence of two cutting-edge therapeutic modalities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62964#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62964"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62964#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62964"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62964\/revisions"}],"predecessor-version":[{"id":62965,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62964\/revisions\/62965"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}